- Home
- NATR vs ADCT Comparison
NATR vs ADCT Comparison
Compare NATR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATR | ADCT |
|---|---|---|
| Founded | 1972 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.6M | 484.4M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NATR | ADCT |
|---|---|---|
| Price | $26.40 | $4.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $28.33 | $7.75 |
| AVG Volume (30 Days) | 98.0K | ★ 630.5K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | 30.86 |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $480,144,000.00 | $81,357,000.00 |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $3.82 | $66.49 |
| P/E Ratio | $25.29 | ★ N/A |
| Revenue Growth | 5.67 | ★ 14.85 |
| 52 Week Low | $11.27 | $1.14 |
| 52 Week High | $28.14 | $4.98 |
Technical Indicators
Market Signals| Indicator | NATR | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 61.38 |
| Support Level | $23.57 | $3.28 |
| Resistance Level | $26.96 | $4.32 |
| Average True Range (ATR) | 0.75 | 0.23 |
| MACD | 0.32 | 0.04 |
| Stochastic Oscillator | 77.89 | 100.00 |
Price Performance
Historical ComparisonAbout NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).